2022: A Look at Key Priorities for Control Bionics

Having achieved a year of strong growth, Control Bionics (ASX:CBL) is forging ahead in the current year to level up its momentum as it aims to emerge as a leading player in the innovative augmentative communications and control (ACC) device space.

The article features a description of the company’s robust first-half performance (including a strong opportunity pipeline and new product launches) and strategic priorities for the year ahead.

Check out the highlights:

  • Control Bionics aims for global expansion of its role in commercialisation, and sale of AAC solutions for people with disabilities.
  • The Company registered 18% revenue growth in the first half.
  • CBL is targeting higher revenue growth across the board by widening its network of partners and sales team channels in the current year.
  • Control Bionics is committed to broadening its product range with an eye-gaze only product, upgradable to Trilogy.

You'll Also Like

Language at Last: A Cerebral Palsy Case Study

In this new case study, we explore how the therapy team worked together to understand his movement patterns and specifically wrist rotation motion so the NeuroNode could be activated and programmed to his abilities, and how the real Ryan was able to shine through.

Read More ›